Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

IVF in IBD: Initial Validation For Success?

Kozuch P.

Dig Dis Sci. 2016 Aug;61(8):2160-1. doi: 10.1007/s10620-016-4232-0. No abstract available.

PMID:
27343039
2.

Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14.

PMID:
27189916
3.

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA.

Inflamm Bowel Dis. 2016 Jun;22(6):1418-24. doi: 10.1097/MIB.0000000000000764.

PMID:
27057680
4.

Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.

Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH.

Eur J Cancer. 2015 Nov;51(16):2314-20. doi: 10.1016/j.ejca.2015.07.031. Epub 2015 Sep 3. Review.

PMID:
26343314
5.

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.

Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034. Epub 2015 Jun 30. Review.

PMID:
26142167
6.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
7.

Gastric Perforation Following Prophylactic Embolization of Right Gastric and Gastroduodenal Arteries Prior to Selective Internal Radiation Therapy.

Shukla PA, Ahuja J, Kurli V, Patel RI, Kozuch PS.

Cardiovasc Intervent Radiol. 2015 Dec;38(6):1645-8. doi: 10.1007/s00270-015-1139-7. Epub 2015 Jun 13.

PMID:
26071106
8.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators.

Lancet. 2014 Jan 4;383(9911):31-9. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.

PMID:
24094768
9.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

10.

Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.

Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS.

J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2.

PMID:
23208490
11.

Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.

Sullivan KM, Kozuch PS.

Cancer J. 2012 Nov-Dec;18(6):633-41. doi: 10.1097/PPO.0b013e318275896f. Review.

PMID:
23187852
12.

Colon adenocarcinoma metastatic to the distal extremity.

Funakoshi T, Visnyei K, Yabe M, Kozuch P.

J Gastrointest Cancer. 2013 Sep;44(3):343-6. doi: 10.1007/s12029-012-9454-6. No abstract available.

PMID:
23109235
13.

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

Azizi E, Kittai A, Kozuch P.

Chemother Res Pract. 2012;2012:198197. doi: 10.1155/2012/198197. Epub 2012 Oct 8.

14.

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease.

Devlin SM, Cheifetz AS, Siegel CA; BRIDGe group.

Gastroenterol Clin North Am. 2012 Jun;41(2):411-28. doi: 10.1016/j.gtc.2012.01.012. Epub 2012 Feb 14. Review.

PMID:
22500526
15.

Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.

Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA.

Inflamm Bowel Dis. 2012 Dec;18(12):2294-300. doi: 10.1002/ibd.22920. Epub 2012 Feb 15.

PMID:
22337359
16.

Case Report: Long-Term Survival in Patients with Initial Lung-Only Metastasis from Pancreatic Adenocarcinoma.

Gotfried JI, Kozuch PS.

J Gastrointest Cancer. 2012 Sep;43 Suppl 1:S50-5. doi: 10.1007/s12029-011-9304-y. No abstract available.

PMID:
21755284
17.

Impact of KRAS Mutations on Management of Colorectal Carcinoma.

Sullivan KM, Kozuch PS.

Patholog Res Int. 2011 Mar 15;2011:219309. doi: 10.4061/2011/219309.

18.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA.

Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6.

PMID:
20451665
19.

Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly.

Holt PR, Kozuch P, Mewar S.

Best Pract Res Clin Gastroenterol. 2009;23(6):889-907. doi: 10.1016/j.bpg.2009.10.010. Review.

20.

Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.

Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, Grossbard M.

Clin Colorectal Cancer. 2009 Jan;8(1):38-42. doi: 10.3816/CCC.2009.n.006.

PMID:
19203895

Supplemental Content

Loading ...
Support Center